ACM
HAE icon

Aster Capital Management’s Haemonetics HAE Stock Holding History

Aster Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-963
Closed -$61.2K – 1018
2026
Q1 		$61.2K Buy
+963
New +$62.7K 0.02% 409
2025
Q2 		– Sell
-951
Closed -$62.3K – 1265
2025
Q1 		$62.3K Buy
+951
New +$64.7K 0.01% 755

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aster Capital Management's HAE Position: Q2 2026 in Review

Aster Capital Management sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 963 shares — an estimated $61.2K sold.

Aster Capital Management first reported a position in HAE in Q1 2025 and held it in 2 quarters. The position peaked at $62.3K in Q1 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Aster Capital Management reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 963 Haemonetics shares in Q2 2026, an estimated $61.2K.
  • Aster Capital Management first reported a position in Haemonetics in Q1 2025 and held it in 2 quarters.
  • Aster Capital Management's Haemonetics position peaked at $62.3K in Q1 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.